Investigating how quinolinate affects immune suppression in glioblastoma
Quinolinate-induced immune suppression in glioblastoma
This study is looking at how a substance called quinolinate affects certain immune cells in the brain that can make it harder for the body to fight glioblastoma, a tough type of brain cancer, with the hope of finding new treatments that could help patients feel better and improve their chances of recovery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | William Beaumont Hospital Research Inst NIH-funded |
| Lab location | 1 site (Royal Oak, United States) |
| Project ID | NIH-10906150 on NIH RePORTER |
What this research studies
This research explores the role of quinolinate, a byproduct of tryptophan metabolism, in glioblastoma, a highly aggressive brain cancer. The study focuses on how quinolinate influences tumor-associated macrophages, which are immune cells that can suppress the body's ability to fight tumors. By understanding the mechanisms of quinolinate's effect on these macrophages, the research aims to develop new therapeutic strategies that could enhance the immune response against glioblastoma. Patients may benefit from potential new treatments that target this metabolic pathway to improve outcomes in glioblastoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with glioblastoma who may benefit from novel immunotherapy approaches.
Not a fit: Patients with other types of cancer or those not diagnosed with glioblastoma may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that enhance the immune system's ability to combat glioblastoma.
How similar studies have performed: Previous research has shown promise in targeting immune suppression in other cancers, but this specific approach in glioblastoma is relatively novel.
Where this research is happening
Royal Oak, United States
- William Beaumont Hospital Research Inst — Royal Oak, United States (Active)
Researchers
- Principal investigator: Chinnaiyan, Prakash — William Beaumont Hospital Research Inst
- Study coordinator: Chinnaiyan, Prakash
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.